ArticleArchives of microbiology2026
Identification of a novel linear B-cell epitope in the N-terminus of varicella-zoster virus glycoprotein B.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Varicella-zoster virus (VZV), a highly contagious human alphaherpesvirus, imposes a substantial economic burden on global healthcare systems. Glycoprotein B (gB), a central fusogen mediating viral entry and cell-cell fusion, represents a promising target for developing VZV vaccines and diagnostic reagents. This study aimed to systematically characterize the antigenicity of VZV gB and map novel linear epitopes to facilitate the development of targeted diagnostics. Methodologically, recombinant glycoprotein B was successfully expressed in a eukaryotic expression system and subsequently purified using nickel-affinity chromatography, and its antigenicity was confirmed with VZV-positive convalescent human serum. Six monoclonal antibodies (mAbs 3B9, 4D2, 5E2, 6G7, 8C9 and 10F11) specifically targeting gB were generated via hybridoma technology. Subsequently, three rounds of progressive truncation using a peptide-overlapping approach and alanine scanning mutagenesis, were employed to precisely identify the antibody binding sites. The results demonstrated that several generated mAbs, particularly the primary detection candidate mAb 6G7, exhibited high titers (up to 1:1024,000) and strong binding affinity (Ka ≈ 7.89 × 10⁸). Crucially, we identified a novel linear B-cell epitope,
Indexed as
Identifiers
42799870What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.